ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Altered Calcium and Vitamin D in PMDD or Severe PMS

This study has been completed.

Sponsors and Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00005119
  Purpose

Osteoporosis has become one of the most widely recognized disorders of our times affecting an estimated 25 million women in this country. Recent evidence has suggested that premenstrual syndrome (PMS) is associated with a calcium deficiency state and bone loss. This may place premenopausal women at greater risk for osteoporosis. An entity such as PMS may be an important physiological marker of a calcium disturbance. The purpose of this investigation is to understand more completely the extent to which calcium balance is disturbed in severe PMS or Premenstrual Dysphoric Disorder (PMDD) by utilizing new tools to assess calcium and bone turnover. The long term objective is to elucidate the pathophysiology of PMDD or severe PMS as it relates to calcium hormones and bone markers. The experimental design involves the comparison between women witn severe PMS and asymptomatic controls.


Condition Intervention
Premenstrual Syndrome
Procedure: Measures of calcium and bone turnover

MedlinePlus related topics:   Premenstrual Syndrome   

ChemIDplus related topics:   Calcium gluconate    Vitamin D    Ergocalciferol   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Diagnostic, Parallel Assignment
Official Title:   Altered Calcium And Vitamin D Metabolism in PMDD

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Study Start Date:   May 2000
Estimated Study Completion Date:   October 2003

  Eligibility
Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Medical history of severe PMS for the PMS group
  • No medical history of PMS for the control group
  • Prospective 2 month documentation of moderate to severe symptoms for the PMS group
  • Prospective 2 month documentation of absent symptoms for the control group
  • General good health
  • Regular menstrual cycles
  • No history of metabolic bone disease

Exclusion Criteria:

  • Amenorrhea
  • Anorexia nervosa
  • Malabsorption
  • Inflammatory bowel disease
  • Erosive gastrointestinal disease
  • Gastrectomy
  • Malignancy
  • Multiple myeloma
  • Primary hyperparathyroidism
  • Use of suppressive doses of thyroxine
  • Cushing's syndrome
  • Use of glucocorticoids or anticonvulsants
  • Use of diuretics
  • Metabolic bone disease
  • Pregnancy or perimenopause or menopause
  • Mental retardation
  • Menstrual irregularity
  • Significant gynecologic abnormality
  • Use of birth control pills
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005119

Locations
United States, New York
St. Luke's-Roosevelt Hospital    
      New York, New York, United States, 10019

Sponsors and Collaborators

Investigators
Principal Investigator:     Susan Thys-Jacobs, MD     St.Luke's-Roosevelt Hospital- Columbia Presbyterian Medical Center    
  More Information

Publications:

Study ID Numbers:   STHYS-JACOBS, DK57869-01
First Received:   April 19, 2000
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00005119
Health Authority:   United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Premenstrual Dysphoric Disorder  
Severe Premenstrual Syndrome  
Calcium metabolism  
Vitamin D  
Bone Markers
Premenopausal
Menstrual Cycle

Study placed in the following topic categories:
Vitamin D
Menstruation Disturbances
Ergocalciferols
Premenstrual Syndrome

Additional relevant MeSH terms:
Disease
Pathologic Processes
Growth Substances
Vitamins
Syndrome
Physiological Effects of Drugs
Bone Density Conservation Agents
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2008




Links to all studies - primarily for crawlers